Abstract 19672: Comparison of Major-bleeding Risk and Health Care Costs Among Treatment-naïve Non-valvular Atrial Fibrillation Patients Initiating Apixaban, Dabigatran, Rivaroxaban or WarfarinAlpesh Amin, Jeffrey Trocio, Kevin Odell et al.|Circulation|2015Cited by 4
Comparison of Short-Term Bleeding-Related Health Care Utilization and Costs Among Treatment-Naïve Nonvalvular Atrial Fibrillation Patients Initiating Apixaban, Dabigatran, Rivaroxaban, or WarfarinAlpesh Amin, Jeffrey Trocio, Allison Keshishian et al.|CHEST Journal|2015Cited by 3
Early Comparison of Major Bleeding, Stroke and Associated Medical Costs Among Treatment-Naive Non-Valvular Atrial Fibrillation Patients Initiating Apixaban, Dabigatran, Rivaroxaban or WarfarinAmin N Alpesh, Jeffrey Trocio, Allison Keshishian et al.|Blood|2015Cited by 3
REAL-WORLD COMPARISON OF MAJOR BLEEDING RISK AMONG UNTREATED NON-VALVULAR ATRIAL FIBRILLATION PATIENTS AND THOSE INITIATING APIXABAN, DABIGATRAN, RIVAROXABAN, OR WARFARINAlpesh Amin, Jeffrey Trocio, Allison Keshishian et al.|Journal of the American College of Cardiology|2016Cited by 2
Treatment and discharge patterns among patients hospitalized with non-valvular atrial fibrillation transitioning from the inpatient to outpatient settingHenry J. Henk, Lien Vo, Feng Cao et al.|Current Medical Research and Opinion|2017Cited by 2